Loading clinical trials...
Loading clinical trials...
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bayer
Collaborators
NCT07350499 · Arterial Thromboembolism, Venous Thromboembolism, and more
NCT07213778 · Symptomatic Venous Thromboembolism (VTE)
NCT07303816 · Venous Thromboembolism, Cancer, and more
NCT05735639 · Venous Thromboembolism, Varicose Veins
NCT06189313 · Pulmonary Embolism, Acute Pulmonary Embolism, and more
US database
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions